Display Settings:

Format

Send to:

Choose Destination
    Curr Opin Investig Drugs. 2008 Mar;9(3):247-55.

    Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis.

    Source

    Wyeth Research, Discovery Translational Medicine, 500 Arcola Rd, Collegeville, PA 19426, USA. hansenm@wyeth.com

    Abstract

    Nuclear hormone receptors, including peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), and the farnesoid X receptor (FXR), are transcription factors involved in the regulation of essential metabolic functions, including glucose and lipid metabolism, reverse cholesterol transport, and the regulation of bile acids. This review summarizes new developments in the use of PPAR, LXR and FXR agonists for the treatment of obesity and cardiovascular diseases, including dyslipidemia and atherosclerosis. Currently available drugs and future areas of research for new therapies are also discussed.

    PMID:
    18311660
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk